Physical status of human papillomavirus in the prognosis of recurrence of low-grade and-high-grade cervical intraepithelial lesions

The study included 168 patients with precancerous cervical lesions 37 with low-grade squamous intraepithelial lesions (LSIL), 131 with high-grade squamous intraepithelial lesions (HSIL), and 150 women, who had not abnormal cervical cell changes. All patients underwent full colposcopy assessment, cytological/histological examination, molecular detection and genotyping of high-risk human papillomavirus. Viral load and physical status of HPV-16 DNA was evaluated in cases of mono-infection (n=208). The prevalence of virus-positive cases among the patients with LSIL/NSIL and healthy women was 78.5 and 50.7 %, respectively. The frequency of recurrence in patients with LSIL and HSIL was found to be determined by the physical status of HPV-16. A significant difference in episomal, mixed and integrated forms of HPV-16 between patients with LSIL/HSIL and patients without abnormal cervical cell changes was found (p=0.0002).

1. Bosch F.X. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin Pharmacother. 2011 Oct; 12 (14): 2189-204. doi: 10.1517/14656566.2011.596527.

2. Apgar B.S., Zoschnick L., Wright T.C.Jr. The 2001 Bethesda System terminology. Am Fam Physician. 2003 Nov 15; 68 (10): 1992-8.

3. Bruni L., Diaz M., Castellsague M., Ferrer E., Bosch F.X., de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis. 2010 Dec 15; 202 (12): 1789-99. doi: 10.1086/657321.

4. IbragimovaM., Tsyganov M, ShpilevaO., ChuruksaevaO.,Bychkov V, Kolomiets L., Litviakov N. HPV status and its genomic integration affect survival of patients with cervical cancer. Neoplasma. 2018 Mar 14; 65 (3): 441-448. doi: 10.4149/neo_2018_170414N277.

5. JiangM., Baseman J.G., KoutskyL.A., Feng Q.,Mao C., KiviatN.B., Xi L.F. Sequence variation of human papillomavirus type 16 and measurement of viral integration by quantitative PCR. J Clin Microbiol. 2009 Mar; 47 (3): 521-6. doi: 10.1128/JCM.02115-08.

6. Kolomiets L.A., Churuksaeva O.N., Shpileva O.V., UrazovaL.N., Rodicheva N.S. Prevalence of various human papillomavirus (hpv) types in patients with cervical intraepithelial neoplasia (cin) and cervical cancer in Tomsk region. Siberian Journal of Oncology. 2012; 3: 41-45. (in Russian).

7. Muhoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., Snijders P.J., Meijer C.J.; International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. New Eng J Med. 2003; 348 (6): 518-527.

8. Belokrinitskaya T.E., Frolova N.I., Turanova O.V., ShemyakinaK.N., Pletneva V.A., SambuevaN.B., Maltseva E.E. The effectiveness and acceptability of screening for human papillomavirus in selfand medical sampling of vaginal discharge. Obstetrics and Gynecology. 2017; 2: 97-105. (in Russian). doi: 10.18565/aig.2017.2.97-105.

9. Sasieni P., Castanon A., Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ. 2009 Jul 28; 339: b2968. doi: 10.1136/bmj.b2968.

10. Novik V.I. Screening for cervical cancer. Practical oncology. 2010; 11 (2): 66-73. (in Russian).

11. Peirson L., Fitzpatrick-Lewis D., Ciliska D., Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013 May 24; 2: 35. doi: 10.1186/2046-4053-2-35.

12. Clavel C., Masure M., Bory J.-P., Putaud I., Mangeonjean C., LorenzatoM., NazeyrollasP., GabrielR., Quereux C., BirembautP. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer. 2001 Jun 15; 84 (12): 1616-23. doi: 10.1054/bjoc.2001.1845.

13. StanleyM. Pathology and epidemiology of HPV infection in females. Gynecol Oncol. 2010 May; 117 (2 Suppl): S5-10. doi: 10.1016/j.ygyno.2010.01.024.

14. Andosova L.D., Kontorshikova K.N., Kachalina O.V The present ideas about the role of infectious warts virus of a human being in the genesis of cervical cancer. Medical Almanach. 2011; 18 (5): 116-120. (in Russian).

15. Vink M.A., Bogaards J.A., van Kemenade F.J., de Melker H.E., Meijer C.J.L.M., Berkhof J. Clinical progression of high-grade cervical intraepithelial neoplasia: estimating the time to preclinical cervical cancer from doubly censored national registry data. Am J Epidemiol. 2013 Oct 1; 178 (7): 1161-9. doi: 10.1093/aje/kwt077.

16. Hu Z., Zhu D., Wang W., Li W., Jia W., Zeng X., Ding W., Yu L., Wang X., Wang L., Shen H., Zhang C., Liu H., Liu X., Zhao Y., Fang X., Li S., Chen W., Tang T., Fu A., Wang Z., Chen G., Gao Q., Li S., Xi L., Wang C., Liao S., Ma X., Wu P., Li K., Wang S., Zhou J., Wang J., Xu X., Wang H., Ma D. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism. Nat Genet. 2015 Feb; 47 (2): 158-63. doi: 10.1038/ng.3178.